

(This is only an advertisement for information purpose and not a Prospectus announcement.)



ANG LIFESCIENCES INDIA LIMITED

Corporate Identification Number: U24230PB2006PLC030341

Our Company was originally incorporated as "ANG Lifesciences India Private Limited" on June 14, 2006 with the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh as a private limited Company under the Companies Act, 1956. On conversion into public limited Company the name of our Company was changed to "ANG Lifesciences India Limited" pursuant to special resolution passed at the Extra Ordinary General Meeting held on January 18, 2010 and a fresh certificate of incorporation dated March 02, 2010 issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. Our company was further converted into private limited Company and the name of our Company was changed to "ANG Lifesciences India Private Limited" pursuant to special resolution passed at the Extra Ordinary General Meeting held on August 31, 2010 and a fresh certificate of incorporation was issued by Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh dated September 22, 2010. Subsequently, on conversion into public limited Company the name of our company again changed to "ANG Lifesciences India Limited" pursuant to special resolution passed at the Extra Ordinary General Meeting held on May 04, 2016 and a fresh certificate of incorporation dated May 18, 2016 issued by the Registrar of Companies, Chandigarh. For further details of our Company, please refer to the chapter titled "History and Certain Corporate Matters" on page 85 of the Prospectus.

Registered Office: Darbara Complex, SCO 113, First Floor, District Shopping Centre, B Block, Ranjit Avenue, Amritsar-143 001. | **Tel:** +91 0183-5133455, 5070118
Manufacturing Unit: Village Kishanpura, P. O. Manpura Baddi Nalagarh Road, Tehsil Nalagarh, Dist. Solan, Himachal Pradesh-173 205. | **Tel:** 92165 08075
E-mail: cs@anglifesciences.com | **Website:** www.anglifesciences.com | **Contact Person:** Ms. Preeti Goel, Company Secretary and Compliance Officer

THE ISSUE

PUBLIC ISSUE OF 15,00,800, EQUITY SHARES OF FACE VALUE OF ₹ 10.00 EACH OF ANG LIFESCIENCES INDIA LIMITED ("ANG" OR "ALIL" OR "THE COMPANY" OR "THE ISSUER") FOR CASH AT A PRICE OF ₹ 80.00 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ 70.00 PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO ₹ 1200.64 LAKHS ("THE ISSUE") OF WHICH, 76,800 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AT A PRICE OF ₹ 80.00 PER EQUITY SHARE AGGREGATING TO ₹ 61.44 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 14,24,000 EQUITY SHARES OF FACE VALUE OF ₹ 10.00 EACH AT AN ISSUE PRICE OF ₹ 80.00 PER EQUITY SHARE AGGREGATING TO ₹ 1139.20 LAKHS IS HERINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.95% AND 27.47%, RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

**THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10.00 EACH AND
THE ISSUE PRICE OF ₹ 80.00 IS 8.00 TIMES OF THE FACE VALUE.**

**THE APPLICATION MUST BE FOR A MINIMUM OF 1,600 EQUITY SHARES AND IN MULTIPLES OF 1,600 EQUITY SHARES THEREAFTER.
FOR FURTHER DETAILS, PLEASE REFER TO "SECTION VIII- ISSUE RELATED INFORMATION" BEGINNING ON PAGE 174 OF THE PROSPECTUS.**

ISSUE

**OPENS ON: TUESDAY, AUGUST 29, 2017
CLOSES ON: THURSDAY AUGUST 31, 2017**

ASBA*

Simple, Safe, Smart way of Application- Make use of it !!!

* Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below.

PLEASE NOTE THAT ALL THE APPLICANTS HAVE TO COMPULSORILY APPLY THROUGH THE ASBA PROCESS.

PROMOTERS OF THE COMPANY: MR. RAJESH GUPTA AND MRS. SARUCHI GUPTA

LISTING: The Equity Shares offered through the Prospectus are proposed to be listed on the SME Platform of BSE Limited. In terms of the Chapter XB of the SEBI (ICDR) Regulations 2009, as amended from time to time, our Company has received an approval letter dated May 02, 2017 from BSE Limited ("BSE") for using its name in the Prospectus for listing of our shares on the SME Platform of BSE Limited. For the purpose of the Issue, the designated Stock Exchange will be the BSE

DISCLAIMER CLAUSE OF SEBI: Since the Issue is being made in terms of Chapter XB of the SEBI (ICDR) Regulations, 2009, the Draft Offer Document was not filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document. Hence, there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire "Disclaimer Clause of SEBI" on page 163 of the Prospectus.

DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by BSE Limited ("BSE") should not in any way be deemed or construed that the Prospectus has been cleared or approved by BSE nor does it certify the correctness or completeness of any of the contents of the Prospectus. The investors are advised to refer to the Prospectus for the full text of the "Disclaimer Clause of BSE" on page 169 of the Prospectus.

IPO GRADING: Since the Issue is being made in terms of Chapter XB of the SEBI (ICDR) Regulations, there is no requirement of appointing an IPO Grading agency.

ADDITIONAL INFORMATION AS REQUIRED UNDER SECTION 30 OF THE COMPANIES ACT, 2013

MAIN OBJECTS AS PER MEMORANDUM OF ASSOCIATION OF THE COMPANY: The main objects of our Company, as contained in our Memorandum of Association, are as set forth below:

"To carry on the business of manufacturers, marketing, traders, importers, exporters, distributors, dealer, retailer, commission agents of all kinds of Pharmaceutical Products, Medicine, Herbal, Allopathic, Homeopathic, Tonic, Syrups, Ayurvedic, feeds, supplements, medical supplements, test control medicines, allopathic pharmaceutical."

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: Authorized Capital: ₹ 5.50 Crores consisting of 55,00,000 Equity Shares of ₹ 10 each; Issued Subscribed and Paid up capital: ₹ 3.68 Crores consisting of 36,82,515 Equity Shares of ₹ 10 each; Proposed post Issue Paid up Capital: ₹ 5.18 Crores consisting of 51,83,315 Equity Shares of ₹ 10 each.

LIABILITY OF MEMBERS: The Liability of the members of the Company is limited.

SIGNATORIES TO MOA AND SHARES SUBSCRIBED:

Original Signatories		Current Promoters	
Name	No. of shares	Name	No. of shares
Marut Arora	5,000	Rajesh Gupta	36,70,515
Hemant Arora	5,000	Saruchi Gupta	10,000
Rajesh Gupta	10,000		

LEAD MANAGER TO THE ISSUE



GUINNESS CORPORATE ADVISORS PRIVATE LIMITED
18, Deshapriya Park Road, Kolkata - 700 026,
West Bengal, India.
Tel.: + 91 33 3001 5555 | **Fax:** + 91 33 3001 5531
Email id: gcapl@guinnessgroup.net
Website: www.guinessonline.net
Contact Person: Ms. Alka Mishra / Mr. Nimisha Joshi
SEBI Registration No.: INM000011930

REGISTRAR TO THE ISSUE



BIG SHARE SERVICES PRIVATE LIMITED
E/2, Ansa Industrial Estate, Sakivihar Road, Sakinaka,
Andheri(E), Mumbai-400 072.
Tel.: 91-22-40430200
Fax: 91-22-28475207
Email: ipo@bigshareonline.com
Website: www.bigshareonline.com
Contact Person: Mr. Babu Rphael
SEBI Registration No.: INR000001385

COMPANY SECRETARY AND COMPLIANCE OFFICER

Ms. Preeti Goel
ANG LIFESCIENCES INDIA LIMITED
Darbara Complex, SCO 113, First Floor,
District Shopping Centre, B Block, Ranjit Avenue,
Amritsar - 143 001.
Tel: +91 0183-5133455, 5070118
Email: cs@anglifesciences.com
Website: www.anglifesciences.com

Investors can contact our Compliance Officer in case of any pre-issue or post-issue related matters such as non-receipt of letters of allotment, credit of allotted shares in the respective beneficiary account etc.

AVAILABILITY OF PROSPECTUS: Investors should note that Investment in Equity Shares involves a degree of risk and investors are advised to refer to the Prospectus and the Risk Factors contained therein, before applying in the Issue. Full copy of the Prospectus shall be available at the website of SEBI at www.sebi.gov.in; the website of Stock Exchange at www.bseindia.com, the website of Lead Manager at www.guinessonline.net and the website of the Issuer Company at www.anglifesciences.com.

AVAILABILITY OF APPLICATION FORMS: Application forms can be obtained from the Stock Exchanges, Issuer Company: ANG Lifesciences India Limited, Lead Manager: Guinness Corporate Advisors Private Limited, Banker to the Issue, Stock Brokers, Registrar to Issue and Share Transfer Agents, Depository Participants. Application Forms can also be downloaded from the website Stock Exchange at www.bseindia.com and the list of SCSBs available on the website of SEBI at www.sebi.gov.in

APPLICATIONS SUPPORTED BY BLOCKED AMOUNT (ASBA): Investors shall apply through the ASBA process. The investors are required to fill the ASBA form and submit the same to their banks. The SCSB will block the amount in the account as per the authority contained in ASBA form. On allotment, amount will be unblocked and account will be debited only to the extent required to be paid for allotment of shares. Hence, there will be no need of refund.

For more details on the ASBA process, please refer to the details given in application forms and Abridged Prospectus and also please refer to the section "Issue Procedure" on page 181 of the Prospectus.

BANKER TO THE ISSUE: ICICI Bank Limited

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus dated August 16, 2017.

FOR ANG LIFESCIENCES INDIA LIMITED

On Behalf of the Board of Directors

Sd/-

Managing Director

Place: Amritsar, Punjab
Date: August 23, 2017

ANG Lifesciences India Limited subject to market conditions, public issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Punjab Chandigarh. The Prospectus shall be available on the website of SEBI at www.sebi.gov.in, the website of the Lead Manager at www.guinessonline.net, the website of the BSE i.e. www.bseindia.com, and website of the Issuer Company at www.anglifesciences.com. Investors should note that investment in Equity Shares involves a high degree of risk. For details investors should refer to and rely on the Prospectus including the section titled "Risk Factors" beginning on page 12 of the Prospectus, which has been filed with ROC.

The Equity Shares have not been and will not be registered under the US Securities Act (the "Securities Act") or any state securities law in United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in the Regulations under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act of 1933.